Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial [0.03%]
社区居住的健康老年人群中每日低剂量阿司匹林与二型糖尿病发病：ASPREE随机安慰剂对照试验的有效性及安全性分析后的分析
Sophia Zoungas,Zhen Zhou,Alice J Owen et al.
Sophia Zoungas et al.
Background: Inflammation has been implicated in the pathogenesis of diabetes. This study investigated the randomised treatment effect of low-dose aspirin on incident type 2 diabetes and fasting plasma glucose (FPG) concen...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2024 Feb;12(2):98-106. DOI:10.1016/S2213-8587(23)00327-3 2024
Analysis of type 2 diabetes heterogeneity with a tree-like representation: insights from the prospective German Diabetes Study and the LURIC cohort [0.03%]
基于树状结构表示的二型糖尿病异质性分析：来自德国糖尿病研究前瞻性研究和LURIC队列的启示
Martin Schön,Katsiaryna Prystupa,Tim Mori et al.
Martin Schön et al.
Background: Heterogeneity in type 2 diabetes can be represented by a tree-like graph structure by use of reversed graph-embedded dimensionality reduction. We aimed to examine whether this approach can be used to stratify ...
Jose C Florez
Jose C Florez
Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations [0.03%]
结束糖尿病的污名和歧视的国际共识陈诉：证据和建议
Jane Speight,Elizabeth Holmes-Truscott,Matthew Garza et al.
Jane Speight et al.
People with diabetes often encounter stigma (ie, negative social judgments, stereotypes, prejudice), which can adversely affect emotional, mental, and physical health; self-care, access to optimal health care; and social and professional op...
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
Enhancing global access to diabetes medicines: policy lessons from the HIV response [0.03%]
改善全球糖尿病药物获取：来自艾滋病应对的政策经验
Felix Teufel,Caroline A Bulstra,Justine I Davies et al.
Felix Teufel et al.
Robert A Hegele
Robert A Hegele
Empagliflozin in chronic kidney disease: nephroprotection is independent of albuminuria, primary kidney disease, and baseline eGFR [0.03%]
恩格列净与慢性肾脏病：恩格列净的肾保护作用独立于蛋白尿、原发性肾脏疾病和基线估算肾小球滤过率
Carmine Zoccali,Francesca Mallamaci
Carmine Zoccali
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial [0.03%]
恩格列净肾脏疾病临床试验(EMPA-KIDNEY)次级分析：不同原发性肾病对恩格列净疗效的影响
EMPA-KIDNEY Collaborative Group
EMPA-KIDNEY Collaborative Group
Background: The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through sl...